Literature DB >> 1451649

[The therapy of the heparin-induced thrombosis-thrombocytopenia syndrome with immunoglobulins].

A Prull1, R Nechwatal, H Riedel, W Mäurer.   

Abstract

A 51-year-old obese woman who had just undergone a second osteotomy for arthrosis of the hip joint was given unfractionated heparin, 7,500 IU subcutaneously three times daily, as thrombosis prophylaxis. Signs of fulminant pulmonary embolism occurred on the 16th postoperative day with a platelet count of 33,000/microliters. Suspected heparin-induced thrombocytopenia and thrombosis (HITT) was confirmed by platelet tests. When heparin had been discontinued immunoglobulin G was administered, seven times 5 g intravenously, in view of the immunological genesis of HITT. In addition thrombolysis treatment with streptokinase combined with phenprocoumon was undertaken, until satisfactory anticoagulation was achieved after 4 days. Platelet count rose to 136,000/microliters within 20 hours of the first immunoglobulin dose. Complete clinical normality was restored, scintigraphy showed no perfusion deficit in the lungs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1451649     DOI: 10.1055/s-2008-1062518

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  5 in total

1.  IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia.

Authors:  Anand Padmanabhan; Curtis G Jones; Shannon M Pechauer; Brian R Curtis; Daniel W Bougie; Mehraboon S Irani; Barbara J Bryant; Jack B Alperin; Thomas G Deloughery; Kevin P Mulvey; Binod Dhakal; Renren Wen; Demin Wang; Richard H Aster
Journal:  Chest       Date:  2017-04-17       Impact factor: 9.410

2.  [Heparin-induced thrombocytopenia Type II (HIT II) A fatal complication of heparin use for thromboembolism prevention].

Authors:  G Hobbensiefken; B Driller; V Studtmann; K Kunz; G Lehrbach
Journal:  Unfallchirurgie       Date:  1996-12

Review 3.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

4.  A Case Report and Literature Review on Argatroban Refractory Heparin-Induced Thrombocytopenia.

Authors:  Imad U Deen; Swati A Jha; Sadaf Mustafa
Journal:  J Community Hosp Intern Med Perspect       Date:  2022-09-09

5.  [Skin and mucosal ulcerations in heparin-induced thrombocytopenia (HIT) II].

Authors:  D Helbig; U Hillen; S Grabbe; J Dissemond
Journal:  Hautarzt       Date:  2007-09       Impact factor: 0.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.